Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

Дата публикации: 13-10-2026 23:00:01

Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers. The findings are published in Blood Cancer Discovery.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Antibody screening approach could speed development of immune-based cancer treatments	0	14.96	15-10-2026
2	Scientists identify clues to making immunotherapy more effective against glioblastoma	0	8.37	13-10-2026
3	New personalised therapy targets chronic blood cancer	0	7.58	02-07-2026
4	Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies	0	9.03	19-05-2026
5	FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies	0	14.59	12-08-2026
6	Насколько близка победа над раком: новые методы лечения	0	0	22-08-2019
7	Tiny silica particles wiped out aggressive prostate cancer in mice	0	7.17	09-07-2026
8	New Combination Therapy Shows Promise for Advanced Bladder Cancer	0	11.16	06-08-2026
9	Promising new options for treating aggressive prostate cancer	7	8	18-10-2023
10	Avammune’s big bet: Why the future of cancer treatment may come in a pill	0	12.86	03-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.29. Источник: medicalxpress.com.